Mission: Glenmark has a rich heritage in offering safe, affordable medications to you and your family. Our well-established foundation motivates and fuels the extensive research and development of innovative products that improve health and well-being for a better world.
Glenmark Pharmaceuticals Inc., USA was established in 2003 as the North American division of Glenmark Pharmaceuticals Ltd. Since its first product launch in January 2005, the company has emerged as one of the leading generic organizations in the U.S.
Currently, Glenmark ranks among the top 80 pharmaceutical companies globally by SCRIP, the largest selling pharmaceutical magazine in the world. Previous SCRIP accolades include, "Best Overall Pipeline'" (2011), "Best Pharma Company in the World – SME" (2008), and "Best Company in an Emerging Market" (2008) in 2008.
Speciality Business: Drug Discovery
Glenmark's ground-breaking drug discovery effort is primarily focused in the areas of inflammation (asthma/COPD, rheumatoid arthritis etc.), metabolic disorders (diabetes, obesity, etc.) and pain (neuropathic pain and inflammatory pain). Glenmark has A robust pipeline of 7 molecules – 4 NCEs and 3 NBEs in various stages of preclinical and preclinical development. Of these, five molecules are in clinical trials. The molecules in clinical development are focusing on advanced treatments for chronic/debilitating diseases and are potential blockbusters with potential peak sales opportunity for each molecule being in the range of USD 1 billion to 3 billion.
Simultaneously, Glenmark has actively followed the strategy of out-licensing its molecules in clinical development to large multinational pharmaceutical organizations. This outlicensing strategy has been successful so far with seven deals struck by the organization in the last nine years collecting USD 206 mn as upfront and milestone payments.
Glenmark's biopharmaceutical research is carried out at its R&D facility in Switzerland. The centre is dedicated to the discovery and development of novel monoclonal antibodies (mAbs). The R&D centre has capabilities to develop mAbs from inception through to preclinical and clinical studies.
Glenmark has also invested in another state-of-the-art R&D facility in Oxford, UK for molecules in clinical development. The R&D facility serves as Glenmark's global centre for clinical development for both small molecules (NCEs) and biologics (NBEs).
Speciality Business: Formulations Businesses
Glenmark's formulations business is currently organized around four regions – India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. India is the largest market in terms of revenue for the organization. The formulations business has six manufacturing facilities; four in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region.
Join the Glenmark Family
Glenmark is more than just a workplace, it’s a family. Our diversified cultures, backgrounds, skills and experience bring creative strength and energy into our organization. We share a common mindset to cherish family values, which we live each day in our own lives and with the patients who take the medicines we develop in an effort to improve health and well-being for a better world.
Since its establishment in the U.S. in 2003, Glenmark has recorded phenomenal growth in a short span of time. We owe this exemplary success to our highly skilled and motivated workforce, as well as our dedication to recruiting top talent.
We value our employees by providing excellent benefits and recognition through an environment that fosters individual development and growth.
Glenmark is an Equal Employment Opportunity Employer.
I have been working at Glenmark Pharmaceuticals USA as a contractor (Less than a year)
Great people to work with
Need smoking gazebo. You don't need people out in front of the building smoking.
Advice to Management
Value the people you have. Great group of people, all areas.
I applied through other source. The process took 2+ weeks. I interviewed at Glenmark Pharmaceuticals USA in May 2017.
Ambitious, motivated, team-oriented, and well as safety. 18 years of Manfacturing experience. Value added and Knowledgeable of multiple tablet presses and Granulation process. Willing to work with others to share current knowledge.